GERON CORP Accrued Bonuses, Current
GERON CORP (GERN) had Accrued Bonuses, Current of $5.94 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current › Employee-related Liabilities, Current
us-gaap:AccruedBonusesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Bonuses, Current $5.94M.
- 2026-03-31: Accrued Bonuses, Current $3.53M.
- 2025-12-31: Accrued Bonuses, Current $10.34M.
- 2024-12-31: Accrued Bonuses, Current $18.06M.
| Period end | Accrued Bonuses, Current |
|---|---|
| 2026-06-30 | $5.94M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.53M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $10.34M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $18.06M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |